ImpediMed Ltd
ASX:IPD

Watchlist Manager
ImpediMed Ltd Logo
ImpediMed Ltd
ASX:IPD
Watchlist
Price: 0.052 AUD Market Closed
Market Cap: 105.2m AUD
Have any thoughts about
ImpediMed Ltd?
Write Note

Gross Margin
ImpediMed Ltd

87.3%
Current
85%
Average
47.2%
Industry

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
87.3%
=
Gross Profit
9m
/
Revenue
10.3m

Gross Margin Across Competitors

Country AU
Market Cap 105.2m AUD
Gross Margin
87%
Country US
Market Cap 205.2B USD
Gross Margin
56%
Country US
Market Cap 193.1B USD
Gross Margin
67%
Country US
Market Cap 148.6B USD
Gross Margin
64%
Country US
Market Cap 132.9B USD
Gross Margin
69%
Country IE
Market Cap 109.9B USD
Gross Margin
65%
Country US
Market Cap 64.8B USD
Gross Margin
45%
Country DE
Market Cap 56.7B EUR
Gross Margin
38%
Country CN
Market Cap 325.5B CNY
Gross Margin
64%
Country US
Market Cap 42.2B USD
Gross Margin
79%
Country US
Market Cap 37.7B USD
Gross Margin
41%
No Stocks Found

ImpediMed Ltd
Glance View

Market Cap
105.2m AUD
Industry
Health Care

ImpediMed Ltd. engages in the development and distribution of bioimpedance devices with a focus on medical applications in the fluid status area. The company is headquartered in Brisbane, Queensland and currently employs 73 full-time employees. The company went IPO on 2007-10-24. The firm develops various medical products that use bioimpedance spectroscopy (BIS) to measure and monitor fluid status and tissue composition. Its product includes SOZO Digital Health Platform. The company is a non-invasive BIS device delivers a snapshot of fluid status and tissue composition in approximately 30 seconds. The Company’s SOZO Applications offer clinicians deeper insights into a patient’s health. SOZO Applications include various software applications, such as L-Dex Analysis for Lymphedema, Body Composition Analysis, Segmental Analysis and HF-Dex Analysis for Heart Failure. The Company’s research devices include SFB7 and ImpediVET. SFB7 single channel, tetrapolar BIS device, which measures fluid status and tissue composition for clinical and research applications.

IPD Intrinsic Value
0.08 AUD
Undervaluation 35%
Intrinsic Value
Price

See Also

Discover More
What is Gross Margin?

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
87.3%
=
Gross Profit
9m
/
Revenue
10.3m
What is the Gross Margin of ImpediMed Ltd?

Based on ImpediMed Ltd's most recent financial statements, the company has Gross Margin of 87.3%.